Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.

Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, Ng KY, Ghoddusi M, Purdon TJ, Wang X, Do T, Pham MT, Brown JM, De Larrea CF, Olson E, Peguero E, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Wendel HG, Riviere I, Liu C, Sather B, Brentjens RJ.

Sci Transl Med. 2019 Mar 27;11(485). pii: eaau7746. doi: 10.1126/scitranslmed.aau7746.

PMID:
30918115
2.

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.

Smith EL, Staehr M, Masakayan R, Tatake IJ, Purdon TJ, Wang X, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Riviere I, Liu C, Brentjens RJ.

Mol Ther. 2018 Jun 6;26(6):1447-1456. doi: 10.1016/j.ymthe.2018.03.016. Epub 2018 Mar 28.

3.

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

Ramagopal UA, Liu W, Garrett-Thomson SC, Bonanno JB, Yan Q, Srinivasan M, Wong SC, Bell A, Mankikar S, Rangan VS, Deshpande S, Korman AJ, Almo SC.

Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4223-E4232. doi: 10.1073/pnas.1617941114. Epub 2017 May 8.

4.

Structure and cancer immunotherapy of the B7 family member B7x.

Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS, Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, Zang X.

Cell Rep. 2014 Nov 6;9(3):1089-98. doi: 10.1016/j.celrep.2014.09.053. Epub 2014 Oct 30.

Supplemental Content

Loading ...
Support Center